TrueBinding is developing TB006, a humanized monoclonal antibody that selectively inhibits Galectin‑3 to reduce chronic inflammaging, with engineered Fc modifications that enable brain penetration and microglial modulation. The company provides an FDA‑authorized Expanded Access Program for patients with dementia or Alzheimer’s who lack other treatment options, while advancing Phase 1b/2a and Phase 2a trials in Alzheimer’s and Parkinson’s disease.
Funding
$227.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammation driven by Galectin‑3 (Gal‑3) contributes to age‑related neurodegeneration and other systemic diseases, yet there are few therapies that can safely and effectively neutralize this target, especially within the brain’s restrictive environment.
Solution
TrueBinding is developing TB006, a monoclonal antibody that selectively inhibits Gal‑3 to reduce inflammaging and its downstream pathology. By demonstrating target engagement and clinical benefit in Alzheimer’s disease—a condition that requires crossing the blood‑brain barrier and modulating microglial activity—TrueBinding aims to validate a platform that can be applied to broader age‑related disorders. The company offers an FDA‑authorized Expanded Access Program, allowing patients with dementia or Alzheimer’s who lack other options to receive TB006 while clinical trials continue. Early Phase 1b/2a data show a one‑month treatment improves Clinical Dementia Rating‑Sum of Boxes scores, suggesting slowed cognitive decline. Ongoing Phase 2a studies are evaluating safety and efficacy in early‑stage Parkinson’s disease, further testing the platform’s systemic applicability.
Target Audience
Primary customers are patients with neurodegenerative diseases such as Alzheimer’s and Parkinson’s who are ineligible for standard clinical trials, as well as healthcare providers and specialty clinics seeking investigational anti‑inflammaging therapies.
Features
- Humanized antibody engineered for high affinity and specificity to Galectin‑3
- Optimized Fc region to enhance brain penetration and microglial modulation
- FDA‑authorized Expanded Access Program providing compassionate use outside trials
- Clinical endpoints include CDR‑SB and other validated cognitive and motor scales
- Scalable manufacturing process designed for systemic administration across multiple indications